Viking Therapeutics (VKTX) Sees Surge Amid Novo Nordisk Clinical Trial Results

Author's Avatar
5 days ago
Article's Main Image

Viking Therapeutics (VKTX, Financial) experienced a significant stock increase, rising by 12% to $46.48. This surge follows Novo Nordisk's announcement of the primary results from its REDEFINE 1 Phase 3 clinical trial. The trial evaluated the weight loss effects of the CagriSema treatment over 68 weeks. Patients treated with CagriSema lost 22.7% of their body weight, which fell short of the market's anticipated 25% weight reduction. Consequently, Novo Nordisk's stock plummeted by over 20%.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.